Concord Biotech Limited — Important, 02-07-2025: General Updates

Concord Biotech has announced a board meeting to review the financial results for the quarter and half-year. The company has made a strategic equity investment of USD 1,500 (approximately ₹12.4 lakh) to acquire 75% ownership in Stellon Biotech Inc, a newly incorporated U.S.-based pharma subsidiary. Stellon will handle marketing, distribution, and commercialization of Concord’s products in the USA, aiming to expand local operations and direct market access. Stellon is currently pre-revenue and will manage end-to-end operations including logistics and customer service.